Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes
AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company’s gene therapies for cancer and diabetes at the following investor conference in December 2022.
Event: RHK 2022 Disruptive Growth Conference
Conference Dates: Dec. 5-6, 2022
Presentation Date: Tuesday, Dec. 6, 2022
Presentation Time: 2:40 p.m. ET
Location: Offices of Reed Smith in New York City
Presenter: Catherine Vaczy, Genprex’s Executive Vice President, General Counsel & Chief Strategy Officer
Ms. Vaczy will be available for Q&A following the presentation and for in-person one-on-one meetings with investors at the RHK Disruptive Growth Conference.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC) (with each of these clinical programs receiving a Fast Track Designation from the Food and Drug Administration) and for small cell lung cancer. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. In models of Type 1 diabetes, the genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In Type 2 diabetes, where autoimmunity is not at play, it is believed that exhausted beta cells are also rejuvenated and replenished.
For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K for the year ended December 31, 2021.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals, including the extent and impact of the COVID-19 pandemic; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships, including those with its third party manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex’s intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-to-present-at-upcoming-december-investor-conference-301691855.html
SOURCE Genprex, Inc.
Related Quotes
By Rachael Green, Benzinga
Temperatures bounce a bit with a few wet days sprinkled in.
Anavex Life Sciences said its experimental Alzheimer's treatment met the goals of a midstage study, leading AVXL stock to rocket early Friday.
Shares of Agenus (NASDAQ: AGEN) rose 12.5% on Friday. One big buyer was Values First Advisors, a financial advisory firm that bought 10,013 shares of the company and now owns 238,514 shares of Agenus. Agenus focuses on immuno-oncology therapies that boost the body's ability to fight cancer and infections by activating T-cell immune responses.
According to the World Health Organization, more than 38 million people worldwide were living with HIV at the end of last year. About 1.2 million people in the U.S. have HIV. In Montgomery County, more than 4,000 people are living with the disease. Montgomery County's Department of Health and Human Services Program Administrator Melvin Cauthen joins FOX 5 to discuss the county's goal of reducing new HIV infections by 90% before 2030.
What does it mean when you get a faint line on a COVID test? There are a few possibilities. Doctors weigh in.
Although hard, it's not impossible, there are healthcare companies with solid earnings and dividend growth that can be had for less than a bill with Ben Franklin's picture on it. Gilead Sciences (NASDAQ: GILD) and Bristol Myers Squibb (NYSE: BMY) have posted triple-digit percentage gains over the past 10 years in revenue, earnings per share (EPS), and total return price. On top of that, shares of Gilead and Bristol can both be bought for less than $90 a share, at least for the time being.
A pancreatic Cancer UK specialist nurse outlines easy-to-ignore signs of the disease
By Faith Ashmore, Benzinga
When everyone around them stops taking pandemic precautions, it gets harder for immunocompromised Americans to protect themselves against COVID.
High intensity exercise may reduce the risk of metastatic cancer according to a new study. Here, experts explain what this means.
One in five people is likely to skip additional breast cancer testing after an abnormal mammogram if there’s a deductible involved, according to a new study. The report, presented at a Radiological Society of North America (RSNA) meeting earlier this week, explored whether costly health insurance deductibles affected a patient’s willingness to undergo breast imaging. […]
Amgen stock dipped Thursday though the company unveiled promising results for its experimental obesity treatment.
Apple (NASDAQ: AAPL) has made no secret about its healthcare market aspirations and has made steady inroads into the space over the past several years. Numerous features on the Apple Watch are geared toward health and fitness. Both the iPhone and the Apple Watch can detect when the user has fallen or has been in a car accident.
But not all experts are convinced
The Laundress is voluntarily recalling about eight million laundry and cleaning products that may contain bacteria that can cause respiratory infections among immunocompromised people. The company said it was issuing the recall Thursday after first warning customers on Nov. 17 to stop using its products. The Laundress said last month it had identified “the potential presence of elevated levels of bacteria” in some of its products and was working with the U.S. Consumer Product Safety Commission.
Cases of gonorrhea — the second most common STI — are skyrocketing in the U.S.
It’s not your imagination. It seems like everyone is getting sick in Florida.
After two years in the background, RSV and the flu have roared to the fore in pediatricians’ offices and children’s hospitals across the country. Pediatric hospitals have been strained for weeks by an early surge in common seasonal pathogens including respiratory syncytial virus, or RSV. Hospitalizations for RSV among kids under 5 are outpacing those for Covid-19, CDC data show.
Al Roker returns to hospital due to blood clot 'complications'
